# Safety of Batracylin in Patients With Solid Tumors and Lymphomas

> **NCT00450502** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Batracylin

## Key facts

- **NCT ID:** NCT00450502
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-24
- **Primary completion:** 2011-04-24
- **Final completion:** 2011-04-24
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450502, "Safety of Batracylin in Patients With Solid Tumors and Lymphomas". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00450502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*